BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16528528)

  • 1. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
    Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
    Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer.
    Yu J; Marsh S; Ahluwalia R; McLeod HL
    Cancer Res; 2003 Oct; 63(19):6170-3. PubMed ID: 14559799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
    Aschele C; Debernardis D; Lonardi S; Bandelloni R; Casazza S; Monfardini S; Gallo L
    J Clin Oncol; 2004 Sep; 22(18):3758-65. PubMed ID: 15365072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
    Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer.
    Yoshimatsu K; Yokomizo H; Fujimoto T; Umehara A; Otani T; Matsumoto A; Osawa G; Shiozawa S; Katsube T; Naritaka Y; Ogawa K
    Anticancer Res; 2007; 27(3B):1641-4. PubMed ID: 17595789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
    Ladner RD; Lynch FJ; Groshen S; Xiong YP; Sherrod A; Caradonna SJ; Stoehlmacher J; Lenz HJ
    Cancer Res; 2000 Jul; 60(13):3493-503. PubMed ID: 10910061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
    Uchida K; Schneider S; Yochim JM; Kuramochi H; Hayashi K; Takasaki K; Yang D; Danenberg KD; Danenberg PV
    Clin Cancer Res; 2005 May; 11(9):3363-8. PubMed ID: 15867236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Saltz LB; Niedzwiecki D; Hollis D; Goldberg RM; Hantel A; Thomas JP; Fields AL; Mayer RJ
    J Clin Oncol; 2007 Aug; 25(23):3456-61. PubMed ID: 17687149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
    Yoshida Y; Hasegawa J; Nezu R; Kim YK; Hirota M; Kawano K; Izumi H; Kohno K
    Cancer Sci; 2011 Mar; 102(3):578-82. PubMed ID: 21205083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
    Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.
    Johnston PG; Lenz HJ; Leichman CG; Danenberg KD; Allegra CJ; Danenberg PV; Leichman L
    Cancer Res; 1995 Apr; 55(7):1407-12. PubMed ID: 7882343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
    Etienne-Grimaldi MC; Formento JL; Francoual M; François E; Formento P; Renée N; Laurent-Puig P; Chazal M; Benchimol D; Delpero JR; Letoublon C; Pezet D; Seitz JF; Milano G
    Clin Cancer Res; 2008 Aug; 14(15):4830-5. PubMed ID: 18676755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma.
    Berglund A; Edler D; Molin D; Nordlinder H; Graf W; Glimelius B
    Anticancer Res; 2002; 22(6B):3653-9. PubMed ID: 12552972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.
    Paradiso A; Simone G; Petroni S; Leone B; Vallejo C; Lacava J; Romero A; Machiavelli M; De Lena M; Allegra CJ; Johnston PG
    Br J Cancer; 2000 Feb; 82(3):560-7. PubMed ID: 10682666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.